Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Study (n=1,836) found olaparib, given after completion of local treatment and neoadjuvant or adjuvant chemotherapy, improved invasive disease-free survival in this patient population (3-year invasive disease-free survival 85.9% v 77.1%; HR 0.58; 99.5% CI 0.41-0.82; P<0.001).

New England Journal of Medicine